Ondansetron for tardive dyskinesia.
D F
DF
Zullino
C B
CB
Eap
P
P
Voirol
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001569:Benzodiazepines; D003024:Clozapine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D004347:Drug Interactions; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D000077152:Olanzapine; D017294:Ondansetron / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D011985:Receptors, Serotonin / Q000187:drug effects; D012702:Serotonin Antagonists / Q000493:pharmacokinetics / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D001569:Benzodiazepines; D010890:Pirenzepine; D017294:Ondansetron; D003024:Clozapine; D000077152:Olanzapine